Paul W H I Parren

List of Publications by Year
in descending order

213	22,943	5876 81	8599 146
papers	citations	h-index	g-index

224	224	224	18421
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Crystal Structure of a Neutralizing Human IgG Against HIV-1: A Template for Vaccine Design. Science, 2001, 293, 1155-1159.	6.0	870
2	Anti-Inflammatory Activity of Human IgG4 Antibodies by Dynamic Fab Arm Exchange. Science, 2007, 317, 1554-1557.	6.0	846
3	Daratumumab, a Novel Therapeutic Human CD38 Monoclonal Antibody, Induces Killing of Multiple Myeloma and Other Hematological Tumors. Journal of Immunology, 2011, 186, 1840-1848.	0.4	841
4	Fc receptor but not complement binding is important in antibody protection against HIV. Nature, 2007, 449, 101-104.	13.7	828
5	Bispecific antibodies: a mechanistic review of the pipeline. Nature Reviews Drug Discovery, 2019, 18, 585-608.	21.5	755
6	Broadly Neutralizing Antibodies Targeted to the Membrane-Proximal External Region of Human Immunodeficiency Virus Type 1 Glycoprotein gp41. Journal of Virology, 2001, 75, 10892-10905.	1.5	734
7	Antibody Protects Macaques against Vaginal Challenge with a Pathogenic R5 Simian/Human Immunodeficiency Virus at Serum Levels Giving Complete Neutralization In Vitro. Journal of Virology, 2001, 75, 8340-8347.	1.5	649
8	Complement Is Activated by IgG Hexamers Assembled at the Cell Surface. Science, 2014, 343, 1260-1263.	6.0	602
9	Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas. Blood, 2004, 104, 1793-1800.	0.6	589
10	The Biological Activity of Human CD20 Monoclonal Antibodies Is Linked to Unique Epitopes on CD20. Journal of Immunology, 2006, 177, 362-371.	0.4	579
11	Effective, low-titer antibody protection against low-dose repeated mucosal SHIV challenge in macaques. Nature Medicine, 2009, 15, 951-954.	15.2	509
12	Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma. MAbs, 2015, 7, 311-320.	2.6	405
13	Monoclonal antibodies targeting <scp>CD</scp>38 in hematological malignancies and beyond. Immunological Reviews, 2016, 270, 95-112.	2.8	280
14	Ebola Virus Can Be Effectively Neutralized by Antibody Produced in Natural Human Infection. Journal of Virology, 1999, 73, 6024-6030.	1.5	268
15	Therapeutic IgG4 antibodies engage in Fab-arm exchange with endogenous human IgG4 in vivo. Nature Biotechnology, 2009, 27, 767-771.	9.4	267
16	Passive immunization with a human monoclonal antibody protects hu-PBL-SCID mice against challenge by primary isolates of HIV-1. Nature Medicine, 1997, 3, 1389-1393.	15.2	262
17	Efficient generation of stable bispecific IgG1 by controlled Fab-arm exchange. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 5145-5150.	3.3	262
18	Effector Function Activities of a Panel of Mutants of a Broadly Neutralizing Antibody against Human Immunodeficiency Virus Type 1. Journal of Virology, 2001, 75, 12161-12168.	1.5	246

#	Article	IF	Citations
19	Contrasting IgG Structures Reveal Extreme Asymmetry and Flexibility. Journal of Molecular Biology, 2002, 319, 9-18.	2.0	246
20	Fine Mapping of the Interaction of Neutralizing and Nonneutralizing Monoclonal Antibodies with the CD4 Binding Site of Human Immunodeficiency Virus Type 1 gp120. Journal of Virology, 2003, 77, 642-658.	1.5	237
21	Binding of Submaximal C1q Promotes Complement-Dependent Cytotoxicity (CDC) of B Cells Opsonized with Anti-CD20 mAbs Ofatumumab (OFA) or Rituximab (RTX): Considerably Higher Levels of CDC Are Induced by OFA than by RTX. Journal of Immunology, 2009, 183, 749-758.	0.4	230
22	GP120: Biologic Aspects of Structural Features. Annual Review of Immunology, 2001, 19, 253-274.	9.5	226
23	The Therapeutic CD38 Monoclonal Antibody Daratumumab Induces Programmed Cell Death via FcÎ³ Receptorâ€“Mediated Cross-Linking. Journal of Immunology, 2016, 197, 807-813.	0.4	225
24	The antiviral activity of antibodies in vitro and in vivo. Advances in Immunology, 2001, 77, 195-262.	1.1	222
25	Neutralizing Antibodies Have Limited Effects on the Control of Established HIV-1 Infection In Vivo. Immunity, 1999, 10, 431-438.	6.6	221
26	Human IgG2 Antibodies against Epidermal Growth Factor Receptor Effectively Trigger Antibody-Dependent Cellular Cytotoxicity but, in Contrast to IgG1, Only by Cells of Myeloid Lineage. Journal of Immunology, 2010, 184, 512-520.	0.4	219
27	In Vitro Characterization of Five Humanized OKT3 Effector Function Variant Antibodies. Cellular Immunology, 2000, 200, 16-26.	1.4	212
28	Towards effective immunotherapy of myeloma: enhanced elimination of myeloma cells by combination of lenalidomide with the human CD38 monoclonal antibody daratumumab. Haematologica, 2011, 96, 284-290.	1.7	212
29	Neutralizing Antibody Fails to Impact the Course of Ebola Virus Infection in Monkeys. PLoS Pathogens, 2007, 3, e9.	2.1	210
30	Antibody fucosylation differentially impacts cytotoxicity mediated by NK and PMN effector cells. Blood, 2008, 112, 2390-2399.	0.6	208
31	Broadly cross-reactive HIV-1-neutralizing human monoclonal Fab selected for binding to gp120-CD4-CCR5 complexes. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 6913-6918.	3.3	203
32	Pre- and Postexposure Prophylaxis of Ebola Virus Infection in an Animal Model by Passive Transfer of a Neutralizing Human Antibody. Journal of Virology, 2002, 76, 6408-6412.	1.5	193
33	Neutralization of Human Immunodeficiency Virus Type 1 by Antibody to gp120 Is Determined Primarily by Occupancy of Sites on the Virion Irrespective of Epitope Specificity. Journal of Virology, 1998, 72, 3512-3519.	1.5	182
34	Crosstalk between Human IgG Isotypes and Murine Effector Cells. Journal of Immunology, 2012, 189, 3430-3438.	0.4	180
35	Heterogeneity of Envelope Molecules Expressed on Primary Human Immunodeficiency Virus Type 1 Particles as Probed by the Binding of Neutralizing and Nonneutralizing Antibodies. Journal of Virology, 2003, 77, 353-365.	1.5	178
36	Cooperative targeting of melanoma heterogeneity with an AXL antibody-drug conjugate and BRAF/MEK inhibitors. Nature Medicine, 2018, 24, 203-212.	15.2	178

#	Article	IF	Citations
37	A Novel Bispecific Antibody Targeting EGFR and cMet Is Effective against EGFR Inhibitorâ€“Resistant Lung Tumors. Cancer Research, 2016, 76, 3942-3953.	0.4	165
38	A Novel Platform for the Potentiation of Therapeutic Antibodies Based on Antigen-Dependent Formation of IgG Hexamers at the Cell Surface. PLoS Biology, 2016, 14, e1002344.	2.6	154
39	Resolution of psoriasis upon blockade of IL-15 biological activity in a xenograft mouse model. Journal of Clinical Investigation, 2003, 112, 1571-1580.	3.9	152
40	Oligomeric and Conformational Properties of a Proteolytically Mature, Disulfide-Stabilized Human Immunodeficiency Virus Type 1 gp140 Envelope Glycoprotein. Journal of Virology, 2002, 76, 7760-7776.	1.5	150
41	Complement-Dependent Tumor Cell Lysis Triggered by Combinations of Epidermal Growth Factor Receptor Antibodies. Cancer Research, 2008, 68, 4998-5003.	0.4	150
42	Direct in Vitro Comparison of Daratumumab with Surrogate Analogs of CD38 Antibodies MOR03087, SAR650984 and Ab79. Blood, 2014, 124, 3474-3474.	0.6	150
43	An Antibodyâ€“Drug Conjugate That Targets Tissue Factor Exhibits Potent Therapeutic Activity against a Broad Range of Solid Tumors. Cancer Research, 2014, 74, 1214-1226.	0.4	149
44	Neutralization Synergy of Human Immunodeficiency Virus Type 1 Primary Isolates by Cocktails of Broadly Neutralizing Antibodies. Journal of Virology, 2001, 75, 12198-12208.	1.5	148
45	HIV-1 antibody â€" debris or virion?. Nature Medicine, 1997, 3, 366-367.	15.2	147
46	Ibrutinib interferes with the cell-mediated anti-tumor activities of therapeutic CD20 antibodies: implications for combination therapy. Haematologica, 2015, 100, 77-86.	1.7	147
47	IL-8 as Antibody Therapeutic Target in Inflammatory Diseases: Reduction of Clinical Activity in Palmoplantar Pustulosis. Journal of Immunology, 2008, 181, 669-679.	0.4	145
48	Dual Mode of Action of a Human Anti-Epidermal Growth Factor Receptor Monoclonal Antibody for Cancer Therapy. Journal of Immunology, 2004, 173, 4699-4707.	0.4	139
49	Molecular Basis of Assembly and Activation of Complement Component C1 in Complex with Immunoglobulin G1 and Antigen. Molecular Cell, 2016, 63, 135-145.	4.5	139
50	Preclinical Evidence for the Therapeutic Potential of CD38-Targeted Immuno-Chemotherapy in Multiple Myeloma Patients Refractory to Lenalidomide and Bortezomib. Clinical Cancer Research, 2015, 21, 2802-2810.	3.2	136
51	Pre-clinical evaluation of CD38 chimeric antigen receptor engineered T cells for the treatment of multiple myeloma. Haematologica, 2016, 101, 616-625.	1.7	136
52	Protection against HIV-1 infection in hu-PBL-SCID mice by passive immunization with a neutralizing human monoclonal antibody against the gp120 CD4-binding site. Aids, 1995, 9, 1-538.	1.0	135
53	Determinants of Human Immunodeficiency Virus Type 1 Envelope Glycoprotein Activation by Soluble CD4 and Monoclonal Antibodies. Journal of Virology, 1998, 72, 6332-6338.	1.5	135
54	When blood transfusion medicine becomes complicated due to interference by monoclonal antibody therapy. Transfusion, 2015, 55, 1555-1562.	0.8	131

#	Article	IF	Citations
55	The IgG Fc Contains Distinct Fc Receptor (FcR) Binding Sites: The Leukocyte Receptors FcÎ³RI and FcÎ³RIIa Bind to a Region in the Fc Distinct from That Recognized by Neonatal FcR and Protein A. Journal of Immunology, 2000, 164, 5313-5318.	0.4	130
56	Species-Specific Determinants in the IgG CH3 Domain Enable Fab-Arm Exchange by Affecting the Noncovalent CH3â€“CH3 Interaction Strength. Journal of Immunology, 2011, 187, 3238-3246.	0.4	128
57	Structures of C1-IgG1 provide insights into how danger pattern recognition activates complement. Science, 2018, 359, 794-797.	6.0	127
58	In vivo Cytotoxicity of Type I CD20 Antibodies Critically Depends on Fc Receptor ITAM Signaling. Cancer Research, 2010, 70, 3209-3217.	0.4	125
59	Inhibition of Virus Attachment to CD4+ Target Cells Is a Major Mechanism of T Cell Lineâ€“adapted HIV-1 Neutralization. Journal of Experimental Medicine, 1997, 186, 1287-1298.	4.2	124
60	Complement in therapy and disease. Molecular Immunology, 2015, 67, 117-130.	1.0	124
61	Effect of Target Dynamics on Pharmacokinetics of a Novel Therapeutic Antibody against the Epidermal Growth Factor Receptor: Implications for the Mechanisms of Action. Cancer Research, 2006, 66, 7630-7638.	0.4	120
62	Complement Activation on B Lymphocytes Opsonized with Rituximab or Ofatumumab Produces Substantial Changes in Membrane Structure Preceding Cell Lysis. Journal of Immunology, 2008, 181, 822-832.	0.4	116
63	Statins Impair Antitumor Effects of Rituximab by Inducing Conformational Changes of CD20. PLoS Medicine, 2008, 5, e64.	3.9	115
64	The Long Third Complementarity-Determining Region of the Heavy Chain Is Important in the Activity of the Broadly Neutralizing Anti-Human Immunodeficiency Virus Type 1 Antibody 2F5. Journal of Virology, 2004, 78, 3155-3161.	1.5	111
65	Assorted Mutations in the Envelope Gene of Simian Immunodeficiency Virus Lead to Loss of Neutralization Resistance against Antibodies Representing a Broad Spectrum of Specificities. Journal of Virology, 2003, 77, 9993-10003.	1.5	110
66	Loss of CD20 and Bound CD20 Antibody from Opsonized B Cells Occurs More Rapidly Because of Trogocytosis Mediated by Fc Receptor-Expressing Effector Cells Than Direct Internalization by the B Cells. Journal of Immunology, 2011, 187, 3438-3447.	0.4	110
67	A Nonfucosylated Variant of the anti-HIV-1 Monoclonal Antibody b12 Has Enhanced FcÎ³RIIIa-Mediated Antiviral Activity In Vitro but Does Not Improve Protection against Mucosal SHIV Challenge in Macaques. Journal of Virology, 2012, 86, 6189-6196.	1.5	110
68	Exhaustion of Cytotoxic Effector Systems May Limit Monoclonal Antibody-Based Immunotherapy in Cancer Patients. Journal of Immunology, 2012, 188, 3532-3541.	0.4	109
69	Genetic Subtypes, Humoral Immunity, and Human Immunodeficiency Virus Type 1 Vaccine Development. Journal of Virology, 2001, 75, 5721-5729.	1.5	108
70	Anti-galactose-Î±-1,3-galactose IgE from allergic patients does not bind Î±-galactosylated glycans on intact therapeutic antibody Fc domains. Nature Biotechnology, 2011, 29, 574-576.	9.4	108
71	Ig <scp>A</scp> <scp>EGFR</scp> antibodies mediate tumour killing in vivo. EMBO Molecular Medicine, 2013, 5, 1213-1226.	3.3	107
72	Reconstructing the human hematopoietic niche in immunodeficient mice: opportunities for studying primary multiple myeloma. Blood, 2012, 120, e9-e16.	0.6	104

#	Article	IF	Citations
73	ADCT-301, a Pyrrolobenzodiazepine (PBD) Dimerâ€“Containing Antibodyâ€“Drug Conjugate (ADC) Targeting CD25-Expressing Hematological Malignancies. Molecular Cancer Therapeutics, 2016, 15, 2709-2721.	1.9	102
74	Molecular Features of the Broadly Neutralizing Immunoglobulin G1 b12 Required for Recognition of Human Immunodeficiency Virus Type 1 gp120. Journal of Virology, 2003, 77, 5863-5876.	1.5	100
75	Absence of specific mucosal antibody responses in HIV-exposed uninfected sex workers from the Gambia. Aids, 2000, 14, 1117-1122.	1.0	97
76	Controlled Fab-arm exchange for the generation of stable bispecific IgG1. Nature Protocols, 2014, 9, 2450-2463.	5.5	97
77	Daratumumab-mediated lysis of primary multiple myeloma cells is enhanced in combination with the human anti-KIR antibody IPH2102 and lenalidomide. Haematologica, 2015, 100, 263-268.	1.7	96
78	Efficient Payload Delivery by a Bispecific Antibodyâ€“Drug Conjugate Targeting HER2 and CD63. Molecular Cancer Therapeutics, 2016, 15, 2688-2697.	1.9	96
79	Antibody and Virus: Binding and Neutralization. Virology, 2000, 270, 1-3.	1.1	91
80	Identification and Characterization of a Peptide That Specifically Binds the Human, Broadly Neutralizing Anti-Human Immunodeficiency Virus Type 1 Antibody b12. Journal of Virology, 2001, 75, 6692-6699.	1.5	85
81	Estimation of dose requirements for sustained in vivo activity of a therapeutic human antiâ€CD20 antibody. British Journal of Haematology, 2008, 140, 303-312.	1.2	83
82	Quantitative Analysis of the Interaction Strength and Dynamics of Human IgG4 Half Molecules by Native Mass Spectrometry. Structure, 2011, 19, 1274-1282.	1.6	82
83	Human Antibody Responses to HIV Type 1 Glycoprotein 41 Cloned in Phage Display Libraries Suggest Three Major Epitopes Are Recognized and Give Evidence for Conserved Antibody Motifs in Antigen Binding. AIDS Research and Human Retroviruses, 1996, 12, 911-924.	0.5	81
84	Immunogenicity screening in protein drug development. Expert Opinion on Biological Therapy, 2007, 7, 405-418.	1.4	80
85	Discovery of amivantamab (JNJ-61186372), a bispecific antibody targeting EGFR and MET. Journal of Biological Chemistry, 2021, 296, 100641.	1.6	80
86	Neutralizing Monoclonal Antibodies Block Human Immunodeficiency Virus Type 1 Infection of Dendritic Cells and Transmission to T Cells. Journal of Virology, 1998, 72, 9788-9794.	1.5	80
87	Unraveling the Macromolecular Pathways of IgG Oligomerization and Complement Activation on Antigenic Surfaces. Nano Letters, 2019, 19, 4787-4796.	4.5	79
88	Tandem Native Mass-Spectrometry on Antibodyâ€“Drug Conjugates and Submillion Da Antibodyâ€“Antigen Protein Assemblies on an Orbitrap EMR Equipped with a High-Mass Quadrupole Mass Selector. Analytical Chemistry, 2015, 87, 6095-6102.	3.2	78
89	Nâ€linked glycosylation is an important parameter for optimal selection of cell lines producing biopharmaceutical human IgG. Biotechnology Progress, 2009, 25, 244-251.	1.3	77
90	In-depth qualitative and quantitative analysis of composite glycosylation profiles and other micro-heterogeneity on intact monoclonal antibodies by high-resolution native mass spectrometry using a modified Orbitrap. MAbs, 2013, 5, 917-924.	2.6	74

#	Article	IF	Citations
91	The in vivo mechanism of action of CD20 monoclonal antibodies depends on local tumor burden. Haematologica, 2011, 96, 1822-1830.	1.7	69
92	DuoBody-CD3xCD20 induces potent T-cell-mediated killing of malignant B cells in preclinical models and provides opportunities for subcutaneous dosing. EBioMedicine, 2020, 52, 102625.	2.7	69
93	Gamma Delta T-Cell Based Cancer Immunotherapy: Past-Present-Future. Frontiers in Immunology, 0, 13, .	2.2	69
94	Antibody Neutralization-Resistant Primary Isolates of Human Immunodeficiency Virus Type 1. Journal of Virology, 1998, 72, 10270-10274.	1.5	68
95	A Novel Human Antibody against Human Immunodeficiency Virus Type 1 gp120 Is V1, V2, and V3 Loop Dependent and Helps Delimit the Epitope of the Broadly Neutralizing Antibody Immunoglobulin G1 b12. Journal of Virology, 2003, 77, 6965-6978.	1.5	67
96	High Turnover of Tissue Factor Enables Efficient Intracellular Delivery of Antibodyâ€“Drug Conjugates. Molecular Cancer Therapeutics, 2015, 14, 1130-1140.	1.9	67
97	Relevance of the antibody response against human immunodeficiency virus type 1 envelope to vaccine design. Immunology Letters, 1997, 57, 105-112.	1.1	65
98	Structure of a High-affinity â€œMimotopeâ€•Peptide Bound to HIV-1-neutralizing Antibody b12 Explains its Inability to Elicit gp120 Cross-reactive Antibodies. Journal of Molecular Biology, 2007, 369, 696-709.	2.0	65
99	Avidity in antibody effector functions and biotherapeutic drug design. Nature Reviews Drug Discovery, 2022, 21, 715-735.	21.5	65
100	Production of stable bispecific IgG1 by controlled Fab-arm exchange. MAbs, 2013, 5, 962-973.	2.6	60
101	Mutation of Y407 in the CH3 domain dramatically alters glycosylation and structure of human IgG. MAbs, 2013, 5, 219-228.	2.6	59
102	Mapping the protein surface of human immunodeficiency virus type 1 gp120 using human monoclonal antibodies from phage display libraries 1 1Edited by F. E. Cohen. Journal of Molecular Biology, 1997, 267, 684-695.	2.0	57
103	Vaccines and the induction of functional antibodies: Time to look beyond the molecules of natural infection?. Nature Medicine, 2000, 6, 123-125.	15.2	57
104	Human IgG is produced in a pro-form that requires clipping of C-terminal lysines for maximal complement activation. MAbs, 2015, 7, 672-680.	2.6	57
105	Functional characterization of a novel anti-B7 monoclonal antibody. European Journal of Immunology, 1992, 22, 3071-3075.	1.6	56
106	A Human CD4 Monoclonal Antibody for the Treatment of T-Cell Lymphoma Combines Inhibition of T-Cell Signaling by a Dual Mechanism with Potent Fc-Dependent Effector Activity. Cancer Research, 2007, 67, 9945-9953.	0.4	54
107	Late B Cell Depletion with a Human Anti-Human CD20 IgG1Î² Monoclonal Antibody Halts the Development of Experimental Autoimmune Encephalomyelitis in Marmosets. Journal of Immunology, 2010, 185, 3990-4003.	0.4	53
108	Interaction of a human FcÎ³RIIb1 (CD32) isoform with murine and human IgG subclasses. International Immunology, 1993, 5, 239-247.	1.8	51

#	Article	IF	Citations
109	Antibodies That Efficiently Form Hexamers upon Antigen Binding Can Induce Complement-Dependent Cytotoxicity under Complement-Limiting Conditions. Journal of Immunology, 2016, 197, 1762-1775.	0.4	50
110	Novel human antibody therapeutics: The age of the Umabs. Biotechnology Journal, 2008, 3, 1157-1171.	1.8	49
111	The antibody zalutumumab inhibits epidermal growth factor receptor signaling by limiting intra- and intermolecular flexibility. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 6109-6114.	3.3	49
112	The INNs and outs of antibody nonproprietary names. MAbs, 2016, 8, 1-9.	2.6	48
113	Combined Fc-protein- and Fc-glyco-engineering of scFv-Fc fusion proteins synergistically enhances CD16a binding but does not further enhance NK-cell mediated ADCC. Journal of Immunological Methods, 2011, 373, 67-78.	0.6	47
114	Mimicking an Induced Self Phenotype by Coating Lymphomas with the NKp30 Ligand B7-H6 Promotes NK Cell Cytotoxicity. Journal of Immunology, 2012, 189, 5037-5046.	0.4	47
115	Neutralizing antibody affords comparable protection against vaginal and rectal simian/human immunodeficiency virus challenge in macaques. Aids, 2016, 30, 1543-1551.	1.0	47
116	Rapid production of recombinant human IgG With improved ADCC effector function in a transient expression system. Biotechnology and Bioengineering, 2010, 105, 350-357.	1.7	44
117	DuoHexaBody-CD37Â®, a novel biparatopic CD37 antibody with enhanced Fc-mediated hexamerization as a potential therapy for B-cell malignancies. Blood Cancer Journal, 2020, 10, 30.	2.8	43
118	Enapotamab vedotin, an AXL-specific antibody-drug conjugate, shows preclinical antitumor activity in non-small cell lung cancer. JCI Insight, 2019, 4, .	2.3	42
119	Crystallization and preliminary structure determination of an intact human immunoglobulin, b12: an antibody that broadly neutralizes primary isolates of HIV-1. Acta Crystallographica Section D: Biological Crystallography, 2001, 57, 168-171.	2.5	41
120	Epidermal Growth Factor Receptor (EGFR) Antibody-Induced Antibody-Dependent Cellular Cytotoxicity Plays a Prominent Role in Inhibiting Tumorigenesis, Even of Tumor Cells Insensitive to EGFR Signaling Inhibition. Journal of Immunology, 2011, 187, 3383-3390.	0.4	41
121	Human Recombinant Antimannan Immunoglobulin G1 Antibody Confers Resistance to Hematogenously Disseminated Candidiasis in Mice. Infection and Immunity, 2006, 74, 362-369.	1.0	40
122	High-Throughput Screening for Internalizing Antibodies by Homogeneous Fluorescence Imaging of a pH-Activated Probe. Journal of Biomolecular Screening, 2016, 21, 12-23.	2.6	40
123	Simian Immunodeficiency Virus (SIV) Envelope-Specific Fabs with High-Level Homologous Neutralizing Activity: Recovery from a Long-Term-Nonprogressor SIV-Infected Macaque. Journal of Virology, 1998, 72, 585-592.	1.5	39
124	The Human CD38 Monoclonal Antibody Daratumumab Shows Antitumor Activity and Hampers Leukemiaâ€“Microenvironment Interactions in Chronic Lymphocytic Leukemia. Clinical Cancer Research, 2017, 23, 1493-1505.	3.2	38
125	CD20 and CD37 antibodies synergize to activate complement by Fc-mediated clustering. Haematologica, 2019, 104, 1841-1852.	1.7	38
126	Fcâ€“Fc interactions of human IgG4 require dissociation of heavy chains and are formed predominantly by the intra-chain hinge isomer. Molecular Immunology, 2013, 53, 35-42.	1.0	37

#	Article	IF	Citations
127	Efficient Generation of Bispecific Murine Antibodies for Pre-Clinical Investigations in Syngeneic Rodent Models. Scientific Reports, 2017, 7, 2476.	1.6	36
128	Weak Fragment Crystallizable (Fc) Domain Interactions Drive the Dynamic Assembly of IgG Oligomers upon Antigen Recognition. ACS Nano, 2020, 14, 2739-2750.	7.3	36
129	Differences in responsiveness to CD3 stimulation between naive and memory CD4+ T cells cannot be overcome by CD28 costimulation. European Journal of Immunology, 1994, 24, 1956-1960.	1.6	35
130	Therapeutic Antibody Gene Transfer: An Active Approach to Passive Immunity. Molecular Therapy, 2004, 10, 411-416.	3.7	33
131	Online nanoliquid chromatographyâ€“mass spectrometry and nanofluorescence detection for high-resolution quantitative N-glycan analysis. Analytical Biochemistry, 2012, 423, 153-162.	1.1	33
132	Enhancing Accuracy in Molecular Weight Determination of Highly Heterogeneously Glycosylated Proteins by Native Tandem Mass Spectrometry. Analytical Chemistry, 2017, 89, 4793-4797.	3.2	33
133	Ebola Virus, Neutrophils, and Antibody Specificity. , 1998, 282, 843a-843.		32
134	Crystal Structure of an Intact Human IgG: Antibody Asymmetry, Flexibility, and a Guide for HIV-1 Vaccine Design. Advances in Experimental Medicine and Biology, 2003, 535, 55-66.	0.8	32
135	Dual Epitope Targeting and Enhanced Hexamerization by DR5 Antibodies as a Novel Approach to Induce Potent Antitumor Activity Through DR5 Agonism. Molecular Cancer Therapeutics, 2020, 19, 2126-2138.	1.9	32
136	C1q binding to surface-bound IgG is stabilized by C1r₂s₂proteases. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	32
137	Antibodies against HIV-1 from Phage Display Libraries: Mapping of an Immune Response and Progress towards Antiviral Immunotherapy (Part 1 of 2). Chemical Immunology and Allergy, 1996, 65, 18-37.	1.7	31
138	Penetration of antibodyâ€opsonized cells by the membrane attack complex of complement promotes Ca²⁺ influx and induces streamers. European Journal of Immunology, 2011, 41, 2436-2446.	1.6	31
139	A novel label-free cell-based assay technology using biolayer interferometry. Biosensors and Bioelectronics, 2017, 87, 388-395.	5.3	31
140	Polymorphism of the Human FcÎ³ Receptor II (CD32): Molecular Basis and Functional Aspects. Immunobiology, 1992, 185, 175-182.	0.8	30
141	Type I CD20 Antibodies Recruit the B Cell Receptor for Complement-Dependent Lysis of Malignant B Cells. Journal of Immunology, 2016, 197, 4829-4837.	0.4	30
142	Erratum to â€œRelevance of the antibody response against human immunodeficiency virus type 1 envelope to vaccine designâ€•[Immunol. Lett. 57 (1997) 105â€“112]. Immunology Letters, 1997, 58, 125-132.	1.1	28
143	HuMab-7D8, a monoclonal antibody directed against the membrane-proximal small loop epitope of CD20 can effectively eliminate CD20low expressing tumor cells that resist rituximab-mediated lysis. Haematologica, 2010, 95, 2063-2071.	1.7	28
144	HER2 monoclonal antibodies that do not interfere with receptor heterodimerization-mediated signaling induce effective internalization and represent valuable components for rational antibody-drug conjugate design. MAbs, 2014, 6, 392-402.	2.6	28

#	Article	IF	Citations
145	Changes to International Nonproprietary Names for antibody therapeutics 2017 and beyond: of mice, men and more. MAbs, 2017, 9, 898-906.	2.6	28
146	A Bispecific Single-Domain Antibody Boosts Autologous VÎ³9VÎ´2-T Cell Responses Toward CD1d in Chronic Lymphocytic Leukemia. Clinical Cancer Research, 2021, 27, 1744-1755.	3.2	28
147	Functional monovalency amplifies the pathogenicity of anti-MuSK IgG4 in myasthenia gravis. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	28
148	Neutralization of IL-8 Prevents the Induction of Dermatologic Adverse Events Associated with the Inhibition of Epidermal Growth Factor Receptor. PLoS ONE, 2012, 7, e39706.	1.1	27
149	Complementâ€mediated tumorâ€specific cell lysis by antibody combinations targeting epidermal growth factor receptor (EGFR) and its variant III (EGFRvIII). Cancer Science, 2011, 102, 1761-1768.	1.7	26
150	Real-time analysis of the detailed sequence of cellular events in mAb-mediated complement-dependent cytotoxicity of B-cell lines and of chronic lymphocytic leukemia B-cells. Molecular Immunology, 2016, 70, 13-23.	1.0	26
151	Enhancing natural killer cell-mediated lysis of lymphoma cells by combining therapeutic antibodies with CD20-specific immunoligands engaging NKG2D or NKp30. OncoImmunology, 2016, 5, e1058459.	2.1	26
152	Fighting the Ebola virus. Nature, 2000, 408, 527-528.	13.7	23
153	A Bispecific Antibody Antagonizes Prosurvival CD40 Signaling and Promotes VÎ³9VÎ´2 T cellâ€“Mediated Antitumor Responses in Human B-cell Malignancies. Cancer Immunology Research, 2021, 9, 50-61.	1.6	23
154	Tumor Cell Killing Mechanisms of Epidermal Growth Factor Receptor (EGFR) Antibodies Are Not Affected by Lung Cancer-Associated EGFR Kinase Mutations. Journal of Immunology, 2008, 180, 4338-4345.	0.4	21
155	Editorial overview: Special section: New concepts in antibody therapeutics: What's in store for antibody therapy?. Current Opinion in Immunology, 2016, 40, vii-xiii.	2.4	20
156	Monoclonal Antibodies against Epidermal Growth Factor Receptor Acquire an Ability To Kill Tumor Cells through Complement Activation by Mutations That Selectively Facilitate the Hexamerization of IgG on Opsonized Cells. Journal of Immunology, 2017, 198, 1585-1594.	0.4	20
157	An integrated science-based approach to drug development. Current Opinion in Immunology, 2008, 20, 426-430.	2.4	19
158	Treatment of Myasthenia Gravis by Preventing Acetylcholine Receptor Modulation. Annals of the New York Academy of Sciences, 2008, 1132, 174-179.	1.8	19
159	Oncogenic KRAS Impairs EGFR Antibodies' Efficiency by C/EBPÎ²-Dependent Suppression of EGFR Expression. Neoplasia, 2012, 14, 190-IN7.	2.3	19
160	Impact of Fc gamma receptor polymorphisms on efficacy and safety of daratumumab in relapsed/refractory multiple myeloma. British Journal of Haematology, 2019, 184, 475-479.	1.2	18
161	Antibody C Region Influences TGN1412-like Functional Activity In Vitro. Journal of Immunology, 2012, 189, 5831-5840.	0.4	17
162	A Directed Molecular Evolution Approach to Improved Immunogenicity of the HIV-1 Envelope Glycoprotein. PLoS ONE, 2011, 6, e20927.	1.1	14

#	Article	IF	Citations
163	Opening the door to innovation. MAbs, 2014, 6, 812-819.	2.6	14
164	Ofatumumab, a Human Mab Targeting a Membrane-Proximal Small-Loop Epitope On CD20, Induces Potent NK Cell-Mediated ADCC.. Blood, 2009, 114, 1725-1725.	0.6	14
165	Mouse/Human Chimeric IgE Antibodies Directed to the House Dust Mite Allergen Der p 2. International Archives of Allergy and Immunology, 1995, 107, 465-466.	0.9	12
166	Two-in-One Designer Antibodies. Science, 2009, 323, 1567-1568.	6.0	12
167	Cysteine-SILAC Mass Spectrometry Enabling the Identification and Quantitation of Scrambled Interchain Disulfide Bonds: Preservation of Native Heavy-Light Chain Pairing in Bispecific IgGs Generated by Controlled Fab-arm Exchange. Analytical Chemistry, 2017, 89, 10873-10882.	3.2	12
168	Antibodies in Human Infectious Disease. Immunologic Research, 2000, 21, 265-278.	1.3	11
169	Role of IgG Fc Receptors in Monoclonal Antibody Therapy of Cancer. , 2014, , 239-255.		11
170	Hexamerization-enhanced CD20 antibody mediates complement-dependent cytotoxicity in serum genetically deficient in C9. Clinical Immunology, 2017, 181, 24-28.	1.4	11
171	Recombinant human monoclonal HLA antibodies of different IgG subclasses recognising the same epitope: Excellent tools to study differential effects of donorâ€specific antibodies. Hla, 2019, 94, 415-424.	0.4	11
172	Preparation of genetically engineered monoclonal antibodies for human immunotherapy. Human Antibodies, 1992, 3, 137-145.	0.6	10
173	Antibody-catalyzed water oxidation: state-of-the-art immunity or ancient history?. Trends in Immunology, 2003, 24, 467-469.	2.9	10
174	High throughput screening for antibody induced complement-dependent cytotoxicity in early antibody discovery using homogeneous macroconfocal fluorescence imaging. Journal of Immunological Methods, 2010, 352, 140-146.	0.6	10
175	Hinge-deleted IgG4 blocker therapy for acetylcholine receptor myasthenia gravis in rhesus monkeys. Scientific Reports, 2017, 7, 992.	1.6	10
176	A quantitative flow cytometric assay for determining binding characteristics of chimeric, humanized and human antibodies in whole blood: Proof of principle with rituximab and ofatumumab. Journal of Immunological Methods, 2013, 388, 8-17.	0.6	9
177	Listening for viral infection. Nature Biotechnology, 2001, 19, 823-824.	9.4	8
178	CD38 Chimeric Antigen Receptor Engineered T Cells As Therapeutic Tools for Multiple Myeloma. Blood, 2014, 124, 4759-4759.	0.6	8
179	Complement activation impacts B-cell depletion by both type I and type II CD20 monoclonal antibodies. Blood, 2008, 112, 4354-4355.	0.6	6
180	Preclinical efficacy studies using HuMax-Axl-ADC, a novel antibody-drug conjugate targeting Axl-expressing solid cancers.. Journal of Clinical Oncology, 2015, 33, 3066-3066.	0.8	6

#	Article	IF	Citations
181	Epidermal Growth Factor Receptor as Target for Perioperative Elimination of Circulating Colorectal Cancer Cells. Journal of Oncology, 2022, 2022, 1-13.	0.6	6
182	Daratumumab, a Novel Human Anti-CD38 Monoclonal antibody shows Anti-Tumor Activity In Mouse Models Of MCL, FL and CLL. Blood, 2013, 122, 378-378.	0.6	5
183	Daratumumab, a Novel Anti-CD38 Monoclonal Antibody Shows Anti-Tumor Activity in CLL and hampers Leukemia-Microenvironment Interactions. Blood, 2014, 124, 4680-4680.	0.6	5
184	Biophysical Characterization and Stability of Modified IgG1 Antibodies with Different Hexamerization Propensities. Journal of Pharmaceutical Sciences, 2022, 111, 1587-1598.	1.6	5
185	Hitting Ebola, to the power of two. Science, 2016, 354, 284-285.	6.0	4
186	CD38-Targeted Immunochemotherapy Of Multiple Myeloma: Preclinical Evidence For Its Combinatorial Use In Lenalidomide and Bortezomib Refractory/Intolerant MM Patients. Blood, 2013, 122, 277-277.	0.6	4
187	Characterization of a Fully Human IgG1 Reconstructed from an Anti-AChR Fab. Annals of the New York Academy of Sciences, 2003, 998, 399-400.	1.8	3
188	Fab-arm exchange. MAbs, 2012, 4, 636-636.	2.6	3
189	Templated insertions at VD and DJ junctions create unique Bâ€cell receptors in the healthy Bâ€cell repertoire. European Journal of Immunology, 2020, 50, 2099-2101.	1.6	3
190	Duobody-CD3xCD20 Shows Unique and Potent Preclinical Anti-Tumor Activity in Vitro and In Vivo, and Is Being Evaluated Clinically in Patients with B-Cell Malignancies. Blood, 2018, 132, 1664-1664.	0.6	3
191	Mind the gap. Methods, 2014, 65, 1-4.	1.9	2
192	Abstract DDT01-03: Discovery and preclinical pharmacology of JNJ-61186372: A novel bispecific antibody targeting EGFR and cMET. , 2014, , .		2
193	Importance of anti-HIV-1 antibodies. Nature Medicine, 1997, 3, 591-591.	15.2	1
194	Antibody Engineering and Therapeutics Conference. MAbs, 2013, 5, 817-825.	2.6	1
195	Celebrating Antibody Therapeutics. Protein Engineering, Design and Selection, 2017, 30, 573-573.	1.0	1
196	Hexamerization-enhanced CD37 and CD20 antibodies synergize in CDC to kill patient-derived CLL cells with unprecedented potency. Molecular Immunology, 2018, 102, 218.	1.0	1
197	Enhanced IgG Hexamerization Mediates Efficient C1q Docking and Complement-Dependent Cytotoxicity; Preclinical Proof Of Concept On Primary CLL and Burkitt Lymphoma. Blood, 2013, 122, 375-375.	0.6	1
198	Use of an antibody-drug conjugate targeting tissue factor to induce complete tumor regression in xenograft models with heterogeneous target expression.. Journal of Clinical Oncology, 2013, 31, 3066-3066.	0.8	1

#	Article	IF	Citations
199	Editorial: Antibody Therapeutics for the Treatment of Filoviral Infection. Frontiers in Immunology, 2022, 13, 859919.	2.2	1
200	Genetic Vaccination: One-Shot Shopping for Immediate and Sustained Protection. Molecular Therapy, 2008, 16, 6-7.	3.7	0
201	Reply to Fab-arm exchange. Nature Biotechnology, 2010, 28, 125-126.	9.4	0
202	Impact of IgG oligomerization state on the potency of complement-dependent cytotoxicity. Immunobiology, 2016, 221, 1143-1144.	0.8	0
203	Response to Comment on â€œType I CD20 Antibodies Recruit the B Cell Receptor for Complement-Dependent Lysis of Malignant B Cellsâ€• Journal of Immunology, 2018, 200, 2517-2517.	0.4	0
204	Mechanisms and in-vivo Significance of HIV-1 Neutralisation. , 2000, , 99-132.		0
205	Abstract B241: Bispecific antibody targeting EGFR and cMet demonstrates superior activity compared to the combination of single pathway inhibitors.. , 2013, , .		0
206	Enhancing Natural Killer Cell-Mediated Lysis of Lymphoma Cells By Combining Therapeutic Antibodies with CD20-Specific Immunoligands Engaging NKG2D or NKp30. Blood, 2014, 124, 1779-1779.	0.6	0
207	Abstract 634: Novel antibody-drug conjugates targeting Axl show anti-tumor activity in solid cancer xenograft models. , 2015, , .		0
208	Abstract A11: Activity of a bispecific antibody targeting EGFR and cMet with enhanced Fc effector function in EGFR mutant setting with cMet pathway activation. , 2015, , .		0
209	Abstract 592: Improving therapeutic activity of agonistic DR5 antibodies by inducing target binding-dependent hexamer formation. , 2016, , .		0
210	Abstract 578: Potent complement-dependent cytotoxicity of tumor cells by target bound hexamerization of EGFR antibodies. , 2016, , .		0
211	Duohexabody-CD37, a Novel Bispecific Antibody with a Hexamerization-Enhancing Mutation Targeting CD37, Demonstrates Superior Complement-Dependent Cytotoxicity in Preclinical B-Cell Malignancy Models. Blood, 2018, 132, 4170-4170.	0.6	0
212	Abstract CN01-02: Maximizing the potential of bispecific antibodies for cancer drug development. , 2019, , .		0
213	Abstract C025: HexaBody-DR5/DR5 (GEN1029) shows potent preclinical antitumor activity in a variety of patient-derived xenograft (PDX) tumor models. , 2019, , .		0